MannKind Corporation (MNKD) Price Target Raised to $11 by Wells Fargo
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowOn June 1, Wells Fargo increased its price target for MannKind Corporation (MNKD) from $10 to $11, maintaining an Overweight rating. This adjustment is attributed to the recent FDA approval of Afrezza Inhalation Powder for pediatric patients aged 6 and older. MannKind also indicated the possibility of receiving up to $35 million in development milestones along with a 10% royalty on net sales. These developments enhance MNKD's potential in the biopharmaceutical market, particularly in treating diabetes in children and adolescents.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Wells Fargo & Company (WFC)
Wells Fargo is a large U.S. bank focused on consumer and commercial banking, mortgages, and wealth management.
The Financials sector covers banks, insurers and capital-markets firms at the center of the economy.
Earlier WFC news
- Alphabet (GOOGL) Stock Rating Confirmed Amid Financing Strategy
- Brookfield Infrastructure (BIP) Positioned for Rail Megamerger Impact
- Wells Fargo (WFC) to Pay $100M for Discrimination in Home Loans
- Analog Devices (ADI) Shares Up 81% Yearly; Raised Price Targets
- Wells Fargo Downgrades Phreesia (PHR) Stock Rating Due to Competition
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
UBS Reiterates Sun Communities (SUI) Rating on Rental Rate Gains
Oct 27
UBS Reiterates Public Storage (PSA) Stock Rating on Storage Recovery
Oct 27
Grameenphone (GP) Reports Return to Growth in Q3 2026 Earnings
Oct 27
Minerals 260 Reports Cash Lift, Bullabulling Expansion in Q1 2026
Oct 27